Sweet Syndrome Following SARS-CoV2 Vaccination
Maria Efenesia Baffa, Roberto Maglie, Neri Giovannozzi, Francesca Montefusco, Stefano Senatore, Daniela Massi, Emiliano Antiga
Abstract
Vaccines are today considered one of the most effective means against the Sars-CoV-2 pandemic. The BNT162b2 vaccine by Pfizer/BioNTech has been massively administered throughout the globe; since its approval, a wide spectrum of cutaneous reactions has been reported. Here we report the case of a 52-year-old Caucasian male who presented with an acute febrile eruption that arose 72 h after the first dose of the BNT162b2 vaccine. The clinicopathological findings were consistent with Sweet's syndrome. The short latency time suggested a possible role of the vaccine in triggering Sweet's syndrome in this case.
Topics & Concepts
VaccinationCoronavirus disease 2019 (COVID-19)MedicinePandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakBroad spectrumPediatricsVirologyOutbreakInternal medicineInfectious disease (medical specialty)Combinatorial chemistryChemistryDiseaseAutoimmune and Inflammatory DisordersDermatological and COVID-19 studiesAutoimmune Bullous Skin Diseases